The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?

The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing? Curr Diab Rep (2017) 17: 124 https://doi.org/10.1007/s11892-017-0954-4 MACROVASCULAR COMPLICATIONS IN DIABETES (VR ARODA AND A GETANEH, SECTION EDITORS) The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing? 1 1,2 Laurentiu M. Pop & Ildiko Lingvay Published online: 23 October 2017 Springer Science+Business Media, LLC 2017 . . Abstract Keywords Sulphonylurea Cardiovascular disease . . . Purpose of Review Sulfonylureas (SUs) are one of the most Cardiovascular safety Type 2 diabetes Healthcare cost commonly used glucose-lowering agents worldwide. While Ischemic preconditioning their efficacy is undisputed, their cardiovascular safety has been debated since the 1970’s. Recent Findings With no dedicated cardiovascular studies Introduction to definitively answer this question, observational studies and meta-analyses abound and have reported divergent The safety profile of pharmacologic agents plays an important results, fueling the controversy. Studies that compared role in defining their risk-benefit ratio, especially when these SUs to metformin or newer agents, like GLP-1 agonists agents are used to treat chronic morbidities which require life- and SGLT2 inhibitors, suggest a difference in cardiovas- long management, like type 2 diabetes mellitus (T2DM). The cular events, yet this is likely the result of beneficial treatment armamentarium for T2DM has expanded impres- effects of the latter. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Diabetes Reports Springer Journals

The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?

Loading next page...
 
/lp/springer_journal/the-infamous-famous-sulfonylureas-and-cardiovascular-safety-much-ado-Vfq5l0CmQe
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Diabetes
ISSN
1534-4827
eISSN
1539-0829
D.O.I.
10.1007/s11892-017-0954-4
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial